All In Biotech

Drug Trial Radar · NCT07017777

A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)

A Phase III, Observer-blind, Randomized Controlled Trial to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)

Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

600

Actual

Start

Nov 14, 2025

Primary completion

Feb 15, 2027

Study completion May 15, 2028

Sponsor

Lead sponsor
CanSino Biologics Inc.Industry
Sponsor type
Industry
First posted
Jun 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 6 weeks, up to 2 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 3 randomized, observation-blinded, active-controlled, parallel-group clinical trial designed to evaluate the immunogenicity, safety, and functional antibody response of the experimental vaccine versus the control vaccine in healthy Thailand infants vaccinated at a 2+1 schedule (2 months, 4 months and 12-15 months). The trial will enroll approximately 600 healthy infants aged 2 months (at least 6 weeks) who will be randomly assigned in a 1:1 ratio to receive either the experimental or control vaccine, with 100 in each group (200 in total) randomized to subgroups and subject to additional immunogenicity assessments. All participants will be evaluated for solicited adverse events for 7 days and unsolicited adverse events for 30 days post each vaccination. Immunogenicity evaluation will be performed in all participants at baseline and post the booster dose, while the sub-cohort participants will be evaluated for post primary series immunogenicity additionally.

Conditions

  • Pneumococcal Infections
  • Streptococcal Infections
  • Bacterial Infections

Interventions

  • PCV13iBiological

    3 doses: 2 months (Dose 1) months (Dose 2), 12-15 months (Booster dose)

  • Prevnar 13Biological

    3 doses: 2 months (Dose 1) months (Dose 2), 12-15 months (Booster dose)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants achieving serotype-specific IgG antibody concentrations ≥ 0.35 µg/mLTime frame: 30 days after the booster dose
  2. Incidence of solicited local and systemic adverse events (AEs)Time frame: Within 7 days after each dose of vaccination

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Faculty of Medicine Siriraj Hospital, Mahidol University

    Bangkok, Thailand

  • King Chulalongkorn Memorial Hospital

    Bangkok, Thailand

  • Phramongkutklao Hospital

    Bangkok, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.